Intro – India’s First local COVID-19 vaccine COVAXIN gets DCGI approval for human trials
Hyderabad: India’s first Covid-19 vaccine, COVAXIN, has received approval from the Drug Controller General of India (DCGI) for further clinical trials Phase I and 2 in infected people.
The vaccine is under development by Hyderbad-based biotechnology firm Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
The clinical trials of the experimental COVID-19 vaccine in humans are scheduled to end by 31 July 2020.
COVAXIN has been expedited through national regulatory protocols, and subjected to “comprehensive pre-clinical studies” according to the company, which reports that the results are “promising” and “show extensive safety and effective immune responses,” the company said in a note.